ADVISORY RESEARCH INC - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 265 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.

Quarter-by-quarter ownership
ADVISORY RESEARCH INC ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$1,319,596
-4.9%
25,333
+15.6%
0.18%
+2.8%
Q2 2023$1,388,038
+481.8%
21,921
+397.5%
0.18%
+356.4%
Q1 2023$238,585
-88.5%
4,406
-87.9%
0.04%
-80.8%
Q2 2022$2,079,000
-16.2%
36,414
-10.2%
0.20%
+2.0%
Q1 2022$2,481,000
+43.2%
40,555
+22.5%
0.20%
+46.3%
Q4 2021$1,733,000
+485.5%
33,104
+317.0%
0.14%
+615.8%
Q3 2021$296,0007,9390.02%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q2 2022
NameSharesValueWeighting ↓
Sarissa Capital Management LP 675,000$26,203,0007.44%
EcoR1 Capital, LLC 244,950$9,509,0003.75%
Redmile Group, LLC 971,565$37,716,0003.60%
Ghost Tree Capital, LLC 120,000$4,658,0001.34%
SENZAR ASSET MANAGEMENT, LLC 144,624$5,614,304,0001.22%
GREAT POINT PARTNERS LLC 100,000$3,882,0001.11%
BB BIOTECH AG 700,000$27,174,0001.07%
Rhenman & Partners Asset Management AB 115,000$4,464,0000.79%
Lisanti Capital Growth, LLC 12,260$476,0000.72%
Rock Springs Capital Management LP 190,000$7,376,0000.55%
View complete list of INTRA CELLULAR THERAPIES INC shareholders